Xencor Inc (NAS:XNCR)
$ 23.97 0.2 (0.84%) Market Cap: 1.48 Bil Enterprise Value: 1.02 Bil PE Ratio: 0 PB Ratio: 2.41 GF Score: 71/100

Xencor Inc at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) Transcript

Feb 09, 2022 / 07:00PM GMT
Release Date Price: $35.32 (+2.17%)
Charles Zhu
Guggenheim Securities, LLC - Analyst

Hello, everyone, and welcome back. I'm Charles Zhu. I'm one of the senior biotech analysts here at Guggenheim Securities. Our next fireside chat will be with Xencor, a clinical-stage antibody and targeted-cytokine platform with an extensive array of various programs. Joining us today is CEO, Bassil Dahiyat. Bassil, thank you very much for your time today. Before we hop into Q&A, could you perhaps give us a three-minute overview of your company platform and pipeline?

Bassil Dahiyat
Xencor, Inc. - President & CEO

Absolutely. Thanks. It's a pleasure to be here at the conference today. Xencor is a protein-engineering company. We engineer antibodies and cytokines, as well as other proteins, to optimize how they engage with the immune system and how they're distributed to the body. We create molecules that have long duration of action, that are highly stable, and that are highly active, and that we hope effective in the treatment of cancers as well as in autoimmune diseases, the two areas we operate. Our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot